Entrada Therapeutics, Inc. Common Stock
$6.90
$0.01 (+0.15%)
$6.67Day Range$7.05
Key Statistics
Market Cap
$268.27M
Shares Outstanding
38.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 29, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$6.91
Day High
$7.05
Day Low
$6.67
Volume
297.4K
VWAP
$6.88
Prev Close
$6.89
Transactions
--
Acc. Volume
--
About Entrada Therapeutics, Inc. Common Stock
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
PHARMACEUTICAL PREPARATIONSSIC 2834152 employeesONE DESIGN CENTER PLACE, BOSTON, MA, 02210857-305-1825IPO Oct 29, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001689375
- Composite FIGI
- BBG00MTSMC16
- Share Class FIGI
- BBG00MTSMC25
- Ticker Root
- TRDA
- SIC Code
- 2834
About Entrada Therapeutics, Inc. Common Stock (TRDA) Stock
Entrada Therapeutics, Inc. Common Stock (TRDA) closed the 2026-09-17 session at $6.90, up 0.15% versus the previous close (+0.01). The stock opened at $6.91 and traded between $6.67 and $7.05 during that session. Session trading volume was 297K shares. The volume-weighted average price (VWAP) is $6.88.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Entrada Therapeutics, Inc. Common Stock has a market capitalization of $268.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TRDA is listed on the XNAS exchange. The company employs approximately 152 people. Entrada Therapeutics, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2021-10-29.
On this page you can find market TRDA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.